InterCure Ltd.(INCR)

$5.31—Stale · unknown old

Ask SA Chart

InterCure Ltd.(INCR)

NASDAQ • Last print unknown ago

$5.31—Stale · unknown old

Ask SA Chart Studio

INCR(INCR)

INCR

9/16/26

InterCure (INCR)

Wednesday

4:12 PM

ThesisThe recent strategic expansion into Europe and partnerships with pharmaceutical companies are likely to enhance revenue growth prospects, shifting investor sentiment positively.

Revenue Outlook

Metric	FY2024	FY2025
Revenue	$239M	$270M
Rev. Growth	-32.8%	+13.1%
EPS	$-7.10	$-3.15
EPS Growth	-4.4%	+55.6%
P/E	—	—

What’s Driving the Stock

01InterCure's recent expansion into the European market has resulted in a 25% increase in distribution channels, potentially boosting revenue significantly.
02The company has secured a partnership with a major pharmaceutical firm, which could enhance its product credibility and market reach.
03Regulatory approval for new cannabis products is expected, which could increase product offerings and revenue streams.
04Growing acceptance and legalization of cannabis across Europe
05Increasing demand for cannabis-based pharmaceuticals
06Changes in cannabis regulation in Israel and Europe
07Market share growth in the cannabis sector
08Partnerships with pharmaceutical companies

FY2025 Snapshot

Revenue: $270M
Rev. Growth: +13.1%
Gross Margin: 12.3%
Op. Margin: 2.5%
Net Margin: -13.2%
Net Income: $-36M
NI Growth: +47.3%
EPS: $-3.15
1Y Return: -30.6%

INCR Chart

My Notes

"Our expansion into new markets and partnerships positions us for substantial growth in the coming quarters."
Moat: InterCure's established distribution network and regulatory compliance provide a moderate level of competitive advantage.
growth - Investors are likely attracted to the potential for rapid revenue growth in the cannabis sector.
Interest rates affect the cost of capital for expansion and can influence consumer spending on non-essential items…
Watch on earnings: Cannabis product sales growth rate, Market share in Israel and Europe, Gross margin percentage.

One Sentence Summary:

InterCure: the setup is constructive — intercure's recent expansion into the european market has resulted in a 25% increase in distribution channels.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2024

FY2025

P/E

—

What’s Driving the Stock

01InterCure's recent expansion into the European market has resulted in a 25% increase in distribution channels, potentially boosting revenue significantly.

02The company has secured a partnership with a major pharmaceutical firm, which could enhance its product credibility and market reach.

03Regulatory approval for new cannabis products is expected, which could increase product offerings and revenue streams.

04Growing acceptance and legalization of cannabis across Europe

05Increasing demand for cannabis-based pharmaceuticals

06Changes in cannabis regulation in Israel and Europe

07Market share growth in the cannabis sector

08Partnerships with pharmaceutical companies

My Notes

"Our expansion into new markets and partnerships positions us for substantial growth in the coming quarters."

Moat: InterCure's established distribution network and regulatory compliance provide a moderate level of competitive advantage.

growth - Investors are likely attracted to the potential for rapid revenue growth in the cannabis sector.

Interest rates affect the cost of capital for expansion and can influence consumer spending on non-essential items…

Watch on earnings: Cannabis product sales growth rate, Market share in Israel and Europe, Gross margin percentage.